感染

订阅

MedSci主页 / 所有栏目 / 感染

生物制剂CD24Fc治疗重症COVID-19：III期临床取得积极进展

2020-06-15 Allan MedSci原创

Covid-19CD24Fc融合蛋白
关注

OncoImmune制药公司近日公布，其实验性生物制剂CD24Fc治疗重症COVID-19患者的III期临床证明了CD24Fc的安全性和有效性。

OncoImmune制药公司近日公布，其实验性生物制剂CD24Fc治疗重症COVID-19患者的III期临床证明了CD24Fc的安全性和有效性。当前COVID-19的治疗策略包括使用阻断病毒复制的抗病毒疗法和针对宿主反应的非抗病毒疗法。由于许多住院患者要么已经很大程度上清除了SARS-CoV-2病毒，要么已经出现针对病毒的免疫力，因此非抗病毒策略已成为治疗重症COVID-19患者的重要方法。

CD24Fc可防止由组织损伤引起的过度炎症。III期试验已招募了230例需要补充氧气的重症COVID-19患者。在试验开始时，患者接受CD24Fc或安慰剂的单次输注，之后随访28天，以确定从重症到轻症的时间（主要终点）。由于该药物通过一种新颖的机制起作用，且该机制与其他实验性疗法没有重复，因此无需排除参加过其他试验的患者。

 

原始出处：

https://www.firstwordpharma.com/node/1732465

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826015, encodeId=b79318260154f, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 06:30:48 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916285, encodeId=ebaa19162852c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat May 15 10:30:48 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653040, encodeId=7cd7165304059, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Nov 10 18:30:48 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524823, encodeId=1350152482308, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jun 17 12:30:48 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594754, encodeId=8eb21594e5473, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 17 12:30:48 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
    2021-04-09 一叶知秋

    #生物制剂#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1826015, encodeId=b79318260154f, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 06:30:48 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916285, encodeId=ebaa19162852c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat May 15 10:30:48 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653040, encodeId=7cd7165304059, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Nov 10 18:30:48 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524823, encodeId=1350152482308, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jun 17 12:30:48 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594754, encodeId=8eb21594e5473, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 17 12:30:48 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
    2021-05-15 juliusluan78

    #III#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1826015, encodeId=b79318260154f, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 06:30:48 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916285, encodeId=ebaa19162852c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat May 15 10:30:48 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653040, encodeId=7cd7165304059, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Nov 10 18:30:48 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524823, encodeId=1350152482308, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jun 17 12:30:48 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594754, encodeId=8eb21594e5473, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 17 12:30:48 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
    2020-11-10 医生2402

    #I期临床#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1826015, encodeId=b79318260154f, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 06:30:48 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916285, encodeId=ebaa19162852c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat May 15 10:30:48 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653040, encodeId=7cd7165304059, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Nov 10 18:30:48 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524823, encodeId=1350152482308, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jun 17 12:30:48 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594754, encodeId=8eb21594e5473, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 17 12:30:48 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
    2020-06-17 guihongzh

    #II期临床#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1826015, encodeId=b79318260154f, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Fri Apr 09 06:30:48 CST 2021, time=2021-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1916285, encodeId=ebaa19162852c, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat May 15 10:30:48 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1653040, encodeId=7cd7165304059, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Tue Nov 10 18:30:48 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524823, encodeId=1350152482308, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Wed Jun 17 12:30:48 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594754, encodeId=8eb21594e5473, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Jun 17 12:30:48 CST 2020, time=2020-06-17, status=1, ipAttribution=)]
    2020-06-17 智智灵药

    #III期#

    0

相关资讯

Stroke：COVID-19期间因短暂性脑缺血发作、轻度和中度卒中而住院的人数减少

COVID-19爆发与短暂、轻度和中度卒中入院率降低相关。考虑到需要预防这些人群中症状的恶化和医疗并发症的发生，卒中治疗网络的重组对于减少由COVID-19引起的附带损害是很有必要的。

BMJ：纽约1000名新冠肺炎患者病程及特征研究

研究认为，纽约医疗中心住院的covid-19患者并发症发病率和死亡率较高，其中急性肾损伤和住院透析率很高，插管时间延长，从症状开始到插管的时间呈双峰分布

6月15日全球新冠肺炎（COVID-19）疫情简报，确诊超798万例

Worldometers世界实时统计数据显示，截至北京时间6月15日8时，全球新冠肺炎累计确诊病例超过798万例，达到7,982,215例，累计死亡病例超过43.5万例，达到435,166例。美国新冠

北京2天新增3例本地确诊，感染源成谜！

首都北京疫情防控的特殊性不言而喻，连续两日出现新增病例，打破55天无本地新增确诊病例局面，感染源目前成谜，这让北京疫情防控受到举国关注。

JAMA：大样本RCT研究泼了冷水，COVID-19康复者血浆仅对重症且非危重患者有效

截止到2020年6月10日，新型冠状病毒（SARS-CoV-2）导致的疾病（COVID-19）已经导致全球超过730万人感染、41万人病死；仍然在以每天7-10万新增确诊的速度增长，且无减缓下来的势头

Heart：Covid-19患者急性心肌损伤常见且与不良预后相关

急性心肌损伤在Covid-19患者中较为常见，并与不良预后相关。

拓展阅读

Critical Care Medicine：气道压力释放通气模式在COVID-19导致急性呼吸 衰竭的患者中的应用：一项单中心随机对照试验

与小潮气量机械通气相比，APRV通气模式并未缩短重症新冠肺炎机械通气患者的机械通气时间，也未改善患者的其他临床结局。

Radiology：超极化氙气MRI显示长期COVID患者的肺部异常

胸部X线片（CXR）是诊断急性COVID-19肺炎最常用的成像方式，对于需要入院治疗的患者，通常会在急性感染三个月后重复检查。

Radiology：基于胸部CT的COVID-19肺炎后1年的预后评估

胸部CT对疾病监测至关重要，时间是充分评估肺部恢复能力的关键因素。

Am J Resp Crit Care：半乳糖凝集素-3抑制剂治疗COVID-19肺炎

在COVID-19肺炎中，吸入GB013治疗的耐受性良好，达到了临床相关的血浆浓度。该研究的数据支持更大规模的临床试验来明确GB013的临床疗效。

European Radiology：如何实现影像学的标准COVID-19全自动预测？

放射组学是一种利用数学算法量化医学成像中病变的表型特征的方法，可用于预测疾病的严重程度和进展。

Lenzilumab 治疗 COVID-19 住院患者，未达到主要终点

FDA 已经拒绝了该公司寻求紧急使用该疗法治疗新住院 COVID-19 患者的请求。美国监管机构确定，它无法得出 lenzilumab 的潜在益处超过潜在风险的结论。